French guidelines for diagnosis and treating latent and active tuberculosis in patients with RA treated with TNF blockers

In a recent paper in the *Annals of the Rheumatic Diseases*, Furst et al proposed preliminary consensus guidelines, elaborated during the “Advances in targeted therapies IV” meeting 2002, for diagnosis and treating latent tuberculosis in patients with rheumatoid arthritis (RA) treated with tumour necrosis factor (TNF) blockers. Some guidelines cannot be universal and must take into account the prevalence of tuberculosis, the type of immigrants, and the prevalence of vaccination with BCG (bacille Calmette-Guérin) in the country where they are proposed. A multidisciplinary French cooperative group termed RATIO (Recherche sur Anti-TNF et Infections Opportunistes), including specialists in infectious diseases, pneumology, gastroenterology, and rheumatology, recently proposed such guidelines adapted for France, which have been validated by the French agency for healthcare product safety (AFSSAPS). These guidelines are intended to help doctors detect and manage tuberculosis in their patients before and after TNF blocker therapy. Moreover, they are now mandatory for all doctors and have to be implemented in addition to the labelling recommendations. They differ in several points from the preliminary consensus guidelines.

Definition of latent tuberculosis and of patients at risk

These patients are defined by the presence of one of the following items:

- A history of tuberculosis treated before 1970, including at least two months with the rifampicin-pyrazinamide combination, or not treated for at least six months
- A weal larger than 10 mm in diameter or a blister in response to an intradermal tuberculin test done more than 10 years after the last BCG vaccination, with no history of correct treatment for active tuberculosis
- Residual radiographic tuberculous lesions larger than 1 cm in size with no certainty that eradicating treatment was received

The small differences between the previous recommendations are:

- The date of the BCG, which is frequently performed in Europe and mandatory in France where 95% of the children are vaccinated by age 6, is taken into account
- Interpretation of the PPD test: choice of a single threshold of 10 mm to consider the test positive in order to simplify the doctor’s practice

Management of latent tuberculosis

Before starting TNF blocker therapy, antituberculous chemoprophylaxis should be initiated in all patients who are at risk of tuberculous reactivation, as defined above.

Three regimens can be used for chemoprophylaxis:

- Rifampicin (Rifadin) 10 mg/kg/day and pyrazinamide (Pirilène) 20 mg/kg/day, each in a single daily dose, for two months. However, the efficacy of this regimen for prophylactic treatment has been validated only in HIV infected patients.
- Rifampicin (Rifadin) 10 mg/kg/day in a single daily dose and isoniazid (Rimifon) 4 mg/kg/day for three months.
- Isoniazid alone for nine months in very elderly patients and in patients with hepatic toxicity or cirrhosis.

The main difference with the previous recommendations is the preferred choice of two drugs including pyrazinamide when possible. This drug may have hepatic toxicity but interest in the use of the combination of rifampicin and pyrazinamide for two months has been recently emphasised in immigrants with resistant BK coming from Asia and Africa.

Chemoprophylaxis should be started at least three weeks before the first infusion of TNF blockers. If latent tuberculosis is diagnosed, it is recommended that gastric aspirates are obtained. If *Mycobacterium tuberculosis* is recovered from the gastric aspirates, the patient should be switched from the prophylactic regimen to a curative regimen.

Management of active tuberculosis diagnosed before or during TNF blocker therapy

Curative treatment includes triple combination therapy with rifampicin (10 mg/kg/day in a single dose), isoniazid (4 mg/kg/day), and pyrazinamide (20 mg/kg/day in a single dose), after which the pyrazinamide is stopped and the two other drugs continued in combination. Ethambutol (20 mg/kg/day) should be added during the first two months if there is a relapse or a suspicion of drug resistance (patient from an endemic area). It is not advisable to start the treatment in hospital departments where other patients with TNF blocker associated immune deficiency are seen.

Can TNF blocker therapy be resumed?

In the absence of prospective data, resumption of TNF blocker therapy is not recommended. If the clinical value of TNF blockers is considered large, the drug should be started at least two months after the end of the antituberculous treatment. It is essential to make sure that there is no clinical or radiographic evidence of active tuberculosis and that tests for the tubercule bacillus are negative.

Current knowledge suggests that isoniazid alone, or with rifampicin, should be given for long term treatment to patients who resume TNF blocker therapy. Careful monitoring by a multidisciplinary team is essential.

Prescription of systemic or local glucocorticoid therapy in patients with tuberculosis receiving TNF blockers

There is no contraindication to intra-articular or systemic glucocorticoid therapy. Glucocorticoid therapy is recommended in patients with tuberculosis milliary, meningitis, or pericarditis. Because rifampicin accelerates the breakdown of glucocorticoids, the glucocorticoid dose should be increased by 40%.

Such recommendations, adapted in every country, should substantially reduce the frequency and severity of tuberculosis occurring during TNF blocker therapy. However, many issues remain unsettled, and changes in these recommendations are likely to occur in the near future.

X Mariette
Service de Rhumatologie, Hôpital Bicêtre, Kremlin Bicêtre, France

D Salmon
Service de Médecine Interne, Hôpital Cochin, Paris, France

Group RATIO
Recherche sur Anti-TNF et Infections Opportunistes

Correspondence to: Professor X Mariette; xavier.mariette@bct.ap-hop-paris.fr

References


**BOOK REVIEW**

Bone and joint futures


“Joint diseases, back complaints, osteoporosis and limb trauma resulting from accidents have an enormous impact on individuals and societies and on healthcare services and economies”. This statement was given by the
Bone and joint futures—"we must act now". The book, which was launched in early 2000, has already been seen as a helpful contribution to understanding the burden of musculoskeletal diseases and their current and future management. It is especially important for the Bone and Joint Decade.

This book is divided into eight different sections. The first chapter focuses on the future provision of care for musculoskeletal conditions, the second on the future burden of the conditions and priorities for health care, and the third chapter on the potential of developments in bioscience and technology. The last five chapters discuss the future diagnoses and management of different conditions: rheumatoid arthritis, osteoarthritis, osteoporosis, chronic musculoskeletal pain, and trauma. Each chapter is written by very competent clinicians and epidemiologists.

The chapters are generally well referenced and provide a lot of useful information to support both clinicians and decision makers in health policy. For example, the demand for care for musculoskeletal conditions is discussed within the framework of changes in demographic patterns, lifestyle changes, peoples’ increasing expectations for health, provision of new treatments, and new technologies as well as the increased costs of health care. Models for care are discussed from different perspectives: the community, the health systems, self-management of patients delivery systems, and also how new information technology can be integrated into the management.

The description of the burden of diseases focuses on the global burden of disease project, the changing demography and, more specifically, on rheumatoid arthritis, osteoarthritis, osteoporosis, and back pain.

All chapters are easy to read, they are divided into subsections, and an index at the end of the book is also helpful for finding specific information. In this way, the book may also be used as a reference for clinicians and managers of health care to identify specific information when needed.

The authors have focused on the major conditions of the musculoskeletal system, but of course, not all conditions have been covered. For example, there are no major discussions on the spondyloarthropathies, on undifferentiated polyarthritis, and on gout. The comprehensiveness of references is a little variable across chapters. The limitation of this book, as with most other books, is that the more recent references are not included. For example, no references from 2002 are included and only a few from 2001. Despite this limitation, the message of this book clearly meets the expectations of the title—focusing on the futures of bone and joint management.

To my knowledge no other book or special issue of a journal covers, the same topic in a similar way. Thus, this book fills an important gap. It will definitely support clinicians when arguing for resources for the care of patients with musculoskeletal diseases and be of special importance to understanding the background and importance of the Bone and Joint Decade.

T K Kvien
Oslo City Department of Rheumatology, Diakonhjemmet Hospital, Box 23 Vinderen, N0319 Oslo, Norway. t.k.kvien@okk.uio.no

FORTHCOMING EVENTS

25th Annual Meeting of the American Society for Bone and Mineral Research (ASBMR)
19–23 September 2003; Minneapolis, Minnesota, USA
Tel: +1 202 367 1161
Fax: +1 202 367 2161
Email: asbmr@dc.sba.com
Website: www.asbmr.org

10th European Pediatric Rheumatology Congress
2–5 October 2003; Stresa, Italy
Contact: Organising Secretariat, ECON srl, Viale della Moscova 16, 20121 Milan, Italy
Tel: +39 022 900 5745
Fax: +39 022 900 5790
Email: econsrl@tin.it
Website: www.pre.org.uk

International Congress on Arthritis in the Elderly
9–11 October 2003; Milan, Italy
Contact: Organising Secretariat: Elena Romero
Tel: +39 02 65 71 200
Fax: +39 02 65 71 270
Email: eldrheum@oic.it

7th EULAR Sonography Course
9–12 October 2003; Rome, Italy
An introductory and practical course on musculoskeletal ultrasonography
Scientific secretariat: Professor Guido Valesini
Email: annamaria.iagrocco@uniroma1.it
Contact: Organising secretariat: Michela Civei, EDRA Spa, Medical Publishing and News Media, Viale Monza, 133 - 20125, Milan, Italy
Tel: +39 (0)2 281 72300
Fax: +39 (0)2 281 72399
Email: edrasongress@dsmedigrup.com

OARSI World Congress on Osteoarthritis
12–15 October 2003; Berlin, Germany
Tel: +1 202 367 1177
Fax: +1 202 367 2177
Email: oarsi@oarsi.org
Website: www.oarsi.org

Fourth International Symposium on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis
14–17 November 2003; Nice, France
Contact: Organisation Secretariat, VP Communication, 108 boulevard G Kleyer, 4000 Liège, Belgium
Tel: +32 (4) 254 12 25
Fax: +32 (4) 254 12 90
Email: yolanda@piettecommunication.com
Website: http://nice.piettecommunication.com

2nd International Forum on Geronto-Rheumatology
27–29 November 2003; Amsterdam, The Netherlands
Contact: Erna Kleinjan, project manager Mark Two Communications, PO Box 358, 3830 AK Leusden
Tel: +31 33 434 5730
Fax: +31 33 434 5720
Email: ekleinjan@marktwo.nl
Website: www.marktwo.nl

IOF World Congress on Osteoporosis
14–18 May 2004; Rio de Janeiro, Brazil
Abstract deadline 14 November 2003
IOF awards are available for scientists:
IOF Claus Christiansen Research Fellowship: €45 000
IOF Servier Young Investigator Fellowship: €40 000
Contact: Congress Secretariat at info@osteofound.org
Website: www.osteofound.org

XIIIth International Conference on Behçet’s Disease
27–31 October 2004; Antalya, Turkey
Contact: Congress Secretariat, Figur Congress and Organization Services Ltd. STL Ayazmaderei Cad. Karadut Sok. No: 7 80088 Dikilitas, Istanbul, Turkey
Tel: +90 (0212) 258 6020
Fax: +90 (0212) 258 6078
Email: behcet2004@figur.net
Website: www.behcet2004.org

Future EULAR congresses
9–12 June 2004; EULAR 2004, Berlin, Germany
8–11 June 2005; EULAR 2005, Vienna, Austria
21–24 June 2006; EULAR 2006, Amsterdam, The Netherlands

Future ACR meetings
24–28 October 2003; 67th Annual Scientific Meeting; Orlando, Florida
16–21 October 2004; 68th Annual Scientific Meeting; San Antonio, Texas

www.annrheumdis.com